Selected a contract manufacturer for commercial launch of M207 Completed first required data set in long-term safety study of M207 Appointed Greg Kitchener as Chief Financial Officer FREMONT,Calif., Nov. 14, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the
FREMONT, Calif. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and webcast to be held on Wednesday, November 14, 2018 at 4:30PM ET .
FREMONT, Calif. , Oct. 23, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced that more than 150 evaluable subjects have completed their six month visit in the M207-ADAM study (the "Study"), a
Live webcast of the event available for analysts and investors FREMONT, Calif. , Oct. 18, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq: ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company developing and commercializing therapies that deliver rapid systemic
Seasoned financial and operational executive further strengthens management team FREMONT, Calif. , Oct. 16, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company developing and commercializing therapies that deliver
FREMONT, Calif. , Oct. 03, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company developing and commercializing therapies that deliver rapid systemic absorption by leveraging its novel and proprietary technology,
Zosano obtains lease financing for the purchase of capital equipment for the scale up and planned commercialization of M207 FREMONT, Calif. , Sept. 26, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company
FREMONT, Calif. , Sept. 19, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using its proprietary Adhesive Dermally-Applied
FREMONT, Calif. , Sept. 06, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, developing and commercializing therapies that deliver rapid systemic absorption by leveraging its novel and proprietary technology
FREMONT, Calif. , Sept. 05, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using its proprietary Adhesive Dermally-Applied
